Elafibranor

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 163 publications

Primary biliary cholangitis: current insights and novel therapies.

Primary biliary cholangitis: current insights and novel therapies.

Journal: Expert review of clinical immunology

Published: May 10, 2026

Network meta-analysis: relative clinical efficacy and safety of elafibranor versus seladelpar as second-line treatment for patients with primary biliary cholangitis.

Network meta-analysis: relative clinical efficacy and safety of elafibranor versus seladelpar as second-line treatment for patients with primary biliary cholangitis.

Journal: Journal of comparative effectiveness research

Published: April 17, 2026

The emerging role of PPARs in primary biliary cholangitis.

The emerging role of PPARs in primary biliary cholangitis.

Journal: Trends in molecular medicine

Published: February 27, 2026

Long-term Treatment With Elafibranor Leads to Biochemical and Symptomatic Improvements for at Least 3 Years in Patients With PBC.

Long-term Treatment With Elafibranor Leads to Biochemical and Symptomatic Improvements for at Least 3 Years in Patients With PBC.

Journal: Gastroenterology & hepatology

Published: February 09, 2026

Elafibranor inhibits neointima formation by downregulating CDK1 expression in carotid artery injury mice model.

Elafibranor inhibits neointima formation by downregulating CDK1 expression in carotid artery injury mice model.

Journal: European journal of pharmacology

Published: January 19, 2026

Consensus statements of the Hellenic Autoimmune Liver Diseases Study Group on the diagnosis and current management of primary biliary cholangitis.

Consensus statements of the Hellenic Autoimmune Liver Diseases Study Group on the diagnosis and current management of primary biliary cholangitis.

Journal: Annals of gastroenterology

Published: December 24, 2025

Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis.

Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis.

Journal: Alimentary pharmacology & therapeutics

Published: December 10, 2025

New and emerging treatments for PBC-related pruritus.

New and emerging treatments for PBC-related pruritus.

Journal: Drugs in context

Published: December 09, 2025

Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVE.

Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVE.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: December 05, 2025

Population Pharmacokinetics and Pharmacokinetics-Pharmacodynamics Analyses of Elafibranor to Support Dose Selection in Primary Biliary Cholangitis.

Population Pharmacokinetics and Pharmacokinetics-Pharmacodynamics Analyses of Elafibranor to Support Dose Selection in Primary Biliary Cholangitis.

Journal: CPT: pharmacometrics & systems pharmacology

Published: October 22, 2025

Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis.

Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis.

Journal: Alimentary pharmacology & therapeutics

Published: October 21, 2025

New therapies for primary biliary cholangitis.

New therapies for primary biliary cholangitis.

Journal: Hepatology international

Published: October 19, 2025

Showing 1-12 of 163

Last Updated: 06/30/2026